Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 406-810-4 | CAS number: 40649-36-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The NOAEL after oral application was determined to be 250 mg/kg bw/day for males and females after 28 days administration to males and female rats.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1190-04-22 to 1990-05-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1981
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Chbb: THOM
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. Thomae GmbH, Biberach, Germany
- Age at study initiation: 9 weeks
- Weight at study initiation (mean): Males: 302 g (287-319 g); Females: 196 g (184-208 g)
- Housing: individually in type III Makrolon cages
- Diet: Altromin Standard Diet TPF® N 1324; ad libitum
- Water. tap water; ad libitum
DETAILS OF FOOD AND WATER QUALITY: The diet was checked periodically by an independent and German Government approved testing laboratory, according to the regulations of the manufacturer. Analysis includes both qualitative and quantitative evaluation for heavy metals, aflatoxins, pesticides and antibiotics. Drinking water employed in this type of study was regularly investigated microbiologically, physico-chemically, and chemically.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22-28
- Humidity (%): 26-4
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5 % Methocel® K4M Premium/Tween 80
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was suspended in the vehicle. Every week three test material concentrations were prepared and stored in brown glass bottles. Before application the test material suspensions were stirred intensively. - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- once daily, 7 times per week
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale:
1000 mg/kg are recommended as highest dose for a 4-week-toxicity-study in the OECD-guidelines. The lower doses were always half of the higher dose.
- Positive control:
- none
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: twice weekly
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes, once weekly
WATER CONSUMPTION: Yes
- Time schedule for examinations: twice weekly
HAEMATOLOGY: Yes
- Time schedule for collection of blood: in treatment week 4
- Anaesthetic used for blood collection: Yes, halothane anesthesia
- Animals fasted: Not specified
- How many animals: all
- Parameters checked: Erythrocyte count (ERY), Leukocyte count (LEUK), Hemoglobin (HB), Packed cell volume (PCV), Platelet count (PLAT), Reticulocyte count (RET), Differential blood cell count % Absolute number of segmented neutrophilic granulocytes(SE), Absolute number of lymphocytes (LY), Mean corpuscular volume (MCV), Mean corpuscular hemoglobin pg content (MCH), Mean corpuscular hemoglobin g/dl concentration (MCHC)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood:
in treatment week 4
- Animals fasted: Not specified
- How many animals: all
- Parameters checked: Sodium, Potassium, Calcium, Chloride, Inorganic phosphorus, Glucose, Urea, Creatinine, Bilirubin Cholesterol, Triglycerides, Alanine aminotransferase, Alkaline phosphatase Aspartate aminotransferase, Protein (total), Albumin
URINALYSIS: Yes
- Time schedule for collection of urine: In study week 4
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes, animals without feed for 18 hours
- Parameters checked: pH value, Protein, Glucose, Urobilinogen, Bilirubin, Blood, Sediment
OPHTHALMOSCOPIC EXAMINATION: Yes
Prior to start of treatment and in study weeks 1 and 4 ophthalmologic examinations were performed in all rats. The anterior chamber of the eye was examined directly with an ophthalmoloscope (Carl Zeiss, No. 29902). The fundus of the eye was examined (indirectly) with a hand slit lamp and a lens. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
The organs below were fixed in ca. 10% formaldehyde solution. In addition a liver sample from the lobus sinister lateralis of the surviving rats was fixed in Lison-Vokaer glycogen fixative. Then the organs for which a stain is given were embedded in paraffin, and sections of them were stained as follows:
Heart, Aorta thoracalis, Lung, Liver, Spleen, Kidneys, Testes, Epididymides, Prostate, Seminal vesicles, Uterus, Ovaries, Urinary bladder, Stomach, Pars proventricularis, Pars fundica, Pars pylorica, Small intestine, Duodenum, Jejunum, Ileum
Large intestine, Caecum, Colon ascendens, Rectum, Mesenterial vessels, Adrenals, Lymph nodes, Lnn. maxillares ant., Lnn. mesenteriales, Thyroids, Parathyroids, Thymus, Pancreas, Bone, Bone marrow (femur), Trachea, Esophagus, Salivary gland Diaphragm, Thigh muscle, Sciatic nerve, Cerebrum, Cerebellum, Medulla oblongata, Spinal cord (I.lumbalis), Pituitary, Adipose tissue (retroperitoneal), Skin with mammary glands, R. thoracalis dextra and/or R. inguinalis sinistra, Eyes, Tongue, Larynx, Nasal and ethmoidal mucosa Middle ear, inner ear
HISTOPATHOLOGY: Yes
The following weights were determined for the surviving rats which were sacrificed at the scheduled times: Body weight (after exsanguination)
Heart, Liver, Kidneys (together), Spleen, Thymus, Testes or ovaries (together) Prostate or uterus, Adrenals (together), Thyroid glands with parathyroids (together), Pituitary, Brain, Eyes (together)
After removing of the ossa frontalia, the skull with brain, pituitary, and eyes, was fixed in ca. 10 % formaldehyde solution for about 2 weeks. The thyroids were left at the larynx and fixed for about 2 weeks in ca. 10% formaldehyde, also. After fixation brain, pituitary, eyes, and thyroids were dissected and weighed. The relative organ weights were calculated per 100 g body weight. - Statistics:
- Body weight gain, food consumption, water consumption, organ weights, the clinico-chemical serum parameters and the haematological parameters haematocrit, haemoglobin and numbers of erythrocytes and leucocytes of the dose groups were compared with those of the control (separately for each sex and time) using the multiple two-sided t-test according to DUNNETT (1955).
Different group sizes or variance non- homogeneity between the dose groups and the control were considered by correcting the critical t-values according to DUNNETT (1964), and in case of variance non-homogeneity by WELCH'S correction of the degrees of freedom (cf. WINER, 1970, pp. 36 - 39).
In cases of very low group sizes or extreme variance non-homogeneity no statistical comparison was performed.
For evaluation of the haematology parameters reticulocytes, eosinophilic, basophilic, juvenile/ bandform neutrophilic granulocytes and the leucocytes (which were not classified further) the procedure of STUCKY and VOLLMAR (1976) (which is based on a linear rank test acc. to KRAUTH, 1971) with the two sided alternative was used.
The parameters segmented neutrophilic granulocytes (SE) and lymphocytes (LY) were evaluated together acc. to UNKELBACH (1980), using the same procedure for the values SE/(SE +LY) . - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- All test material treated rats showed salivation and burrowing in the litter directly after treatment, symptoms which are often seen after administration of substances with bad taste. Additional abdominal or lateral position, followed by reduced spontaneous activity, was only observed in the 1000 mg/kg group. In study weeks 3 and 4 these symptoms were only sporadically seen in males, while in some females they lasted up to the end of the study.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no mortalities after treatment with the test item.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Up to 1000 mg/kg there were no significant differences in body weight gain, as compared to the controls, neither in males nor in females.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- In all dose groups the food consumption values were comparable to those of the controls.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- In the 1000 mg/kg group water consumption was increased in males only at the end of the study, and moderately increased in the females during the whole course of the study.
- Ophthalmological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- As a finding, which is characteristic for young rats of this rat strain, rests of the membrana pupillaris persis-tens were seen in treated and untreated rats with the same frequency
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There was no indication of effects of the test material on the red or white blood cell counts.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In males of the highest dose group (group 7) the serum glucose values were slightly decreased. A significant increase in cholesterol and total protein values was found in all male dose groups (groups 5-7). The females of groups 6 and 7 showed slightly increased ALAT activity. The other serum parameters of the test item treated groups were in all normal, inspite of sporadic significant deviations from the controls - as were the urine parameters - and did not indicate test material induced impairment of physiological functions
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The increased adrenal weights, seen after the highest dose (1000 mg/kg), were considered as adaptation syndrome. The increased liver weight (also seen only in the highest dose group) is a consequence of increased metabolic activity.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Gross pathology findings were reddish-coloured contents in the intestines and increased size of Beyer's plaques in test substance treated females.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Mamma: Test material effects could be excluded after examination of all groups.
Liver: In rats of the highest dose group reduced glycogen contents was seen.
Intestines: Test material-related hyperplasia of the lymphatic tissues with sporadic calcium depositions was seen in the small intestines. Lymphatic hyperplasia is known to occur in the intestinal tract of untreated rats also. Therefore the finding of one affected animal in the 250 mg/kg group is without toxico-logical relevance (see table 1 in section 'Any other information on results incl. tables'). - Histopathological findings: neoplastic:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 250 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- clinical signs
- histopathology: non-neoplastic
- Key result
- Critical effects observed:
- no
- Conclusions:
- The NOAEL after oral application was determined to be 250 mg/kg bw/day for males and females after 28 days administration to males and female rats.
- Executive summary:
A study according OECD TG 407 was conducted to determine the oral toxicity after repeated administration of the test item to Wistar rats by gavage. The test material was administered as suspension in aqueous 0.5 % Methocel® K4M Premium/Tween 80.
Both substances were given to rats in daily oral doses of 250, 500, and 1000 mg/kg bw/day. Each group consisted of 10 animals (5 m, 5 f). Appearance and behaviour of all rats were checked daily. Body weight and water consumption were determined twice weekly and food consumption once weekly. In weeks 1 and 4 ophthalmological inspections were performed. Haematological examinations and clinico-chemical analyses of serum and urine were carried out in all animals in treatment week 4. At the end of the 4-week treatment period all animals were sacrificed and necropsied. 12 organs were weighed from each animal and a maximum of 38 organs and tissues per animal were subjected to histopathological examination.There were no mortalities after treatment with the test substance. All rats showed salivation and burrowing in the litter after treatment. Abdominal and lateral position, followed by reduced spontaneous activity, were only seen in the 1000 mg/kg group. There were no significant differences to the control in body weight gain and food consumption up to the highest dose group. But water consumption was increased in the 1000 mg/kg group. The hematological parameters gave no indication of test material effects on the blood picture. The clinico-chemical examinations showed a clear increase of serum cholesterol and total protein values in the males of all three dose groups, and in the highest dose group slightly reduced serum glucose values in addition. The females only showed slightly increased alanine aminotransferase activity from 500 mg/kg on. There were no ophthalmological findings related to the test substance. Gross pathology findings were reddish-coloured contents in the intestines and increased size of Beyer's plaques in test substance treated females. The histopathological finding was lymphatic hyperplasia. As this finding was only seen in one rat of the 250 mg/kg group, 250 mg/kg are considered as still tolerated. No histological correlate to the increased adrenal and liver weights of the 1000 mg/kg dose group was found. The weight alterations are considered to be attributable to an adaptation syndrome and increased metabolie activity.
The NOAEL after oral application was determined to be 250 mg/kg bw/day for males and females after 28 days administration to males and female rats.
Reference
Intestines:
Test material-related hyperplasia of the lymphatic tissue with sporacid calcium deposition was seen in the small intestines. The frequecy was as follows
Table 1:
Dose |
0 mg/kg |
250 mg/kg |
500 mg/kg |
1000 mg/kg |
||||
Sex |
m |
f |
m |
f |
m |
f |
m |
f |
Lymphatic hyperplasia |
0 |
0 |
0 |
1 |
0 |
4 |
0 |
3 |
Calcification |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 250 mg/kg bw/day
- Study duration:
- subacute
- Experimental exposure time per week (hours/week):
- 4
- Species:
- rat
- Quality of whole database:
- OECD TG 407
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A study according OECD TG 407 was conducted
to determine the oral toxicity after repeated administration of the test
item to Wistar rats by gavage. The test material was administered as
suspension in aqueous 0.5 % Methocel® K4M Premium/Tween 80.
Both substances were given to rats in daily oral doses of 250, 500, and
1000 mg/kg bw/day. Each group consisted of 10 animals (5 m, 5 f).
Appearance and behaviour of all rats were checked daily. Body weight and
water consumption were determined twice weekly and food consumption once
weekly. In weeks 1 and 4 ophthalmological inspections were performed.
Haematological examinations and clinico-chemical analyses of serum and
urine were carried out in all animals in treatment week 4. At the end of
the 4-week treatment period all animals were sacrificed and necropsied.
12 organs were weighed from each animal and a maximum of 38 organs and
tissues per animal were subjected to histopathological examination.
There were no mortalities after treatment with the test substance. All rats showed salivation and burrowing in the litter after treatment. Abdominal and lateral position, followed by reduced spontaneous activity, were only seen in the 1000 mg/kg group. There were no significant differences to the control in body weight gain and food consumption up to the highest dose group. But water consumption was increased in the 1000 mg/kg group. The hematological parameters gave no indication of test material effects on the blood picture. The clinico-chemical examinations showed a clear increase of serum cholesterol and total protein values in the males of all three dose groups, and in the highest dose group slightly reduced serum glucose values in addition. The females only showed slightly increased alanine aminotransferase activity from 500 mg/kg on. There were no ophthalmological findings related to the test substance. Gross pathology findings were reddish-coloured contents in the intestines and increased size of Beyer's plaques in test substance treated females. The histopathological finding was lymphatic hyperplasia. As this finding was only seen in one rat of the 250 mg/kg group, 250 mg/kg are considered as still tolerated. No histological correlate to the increased adrenal and liver weights of the 1000 mg/kg dose group was found. The weight alterations are considered to be attributable to an adaptation syndrome and increased metabolie activity.
The NOAEL after oral application was determined to be 250 mg/kg bw/day for males and females after 28 days administration to males and female rats (reference 7.5.1-1).
Justification for classification or non-classification
Classification, Labelling, and Packaging
Regulation (EC) No 1272/2008
The available experimental test
data are reliable and suitable for classification purposes under
Regulation (EC) No 1272/2008. Based on available data on repeated dose
toxicity, the test item is not classified for repeated dose toxicity
according to Regulation (EC) No 1272/2008 (CLP), as amended for the
twelfth time in Regulation (EU) 2019/521.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.